• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Blue Lake reports positive data from Phase I RSV vaccine trial

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Nov 08, 2022 at 11:32: AM
via Blue Lake Biotechnology has reported positive interim findings from a Phase I clinical trial of its intranasal vaccine candidate, BLB201, to prevent severe respiratory syncytial virus (RSV)-linked disease.

article source
 




Top Bottom
Back
Quote